Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype

Brain Pathology

Volumn 27, Issue 6, 2017, Pages 723-736

  Mann, David M A ^a   Snowden, Julie S ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

clinical phenotypes; frontotemporal lobar degeneration; genetics; neuropathology; pathogenesis

Indexed keywords

PROGRANULIN; RNA BINDING PROTEIN FUS; TAR DNA BINDING PROTEIN; TAU PROTEIN; C9ORF72 PROTEIN, HUMAN; DNA BINDING PROTEIN; GRN PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE C9ORF72; MAPT PROTEIN, HUMAN; SIGNAL PEPTIDE;

AMYOTROPHIC LATERAL SCLEROSIS; C9ORF72 GENE; DISEASE ASSOCIATION; FAMILIAL DISEASE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE; GRN GENE; HISTOLOGY; MAPT GENE; NEUROPATHOLOGY; PATHOGENESIS; PHENOTYPE; PROGRESSIVE NONFLUENT APHASIA; REVIEW; RNA METABOLISM; SEMANTIC DEMENTIA; TDP 43 PROTEINOPATHY; APHASIA; BRAIN; GENETICS; HUMAN; MUTATION; PATHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; APHASIA; BRAIN; C9ORF72 PROTEIN; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PHENOTYPE; RNA-BINDING PROTEIN FUS; TAU PROTEINS; TDP-43 PROTEINOPATHIES;

EID: 85014286240     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12486     Document Type: Review

References (181)

1. Acosta-Cabronero J, Patterson K, Fryer TD, Hodges JR, Pengas G, Williams GB et al (2011) Atrophy, hypometabolism and white matter abnormalities in semantic dementia tell a coherent story. Brain 134:2025–2035.
2. Agosta F, Henry RG, Migliaccio R, Neuhaus J, Miller BL, Dronkers NF et al (2010) Language networks in semantic dementia. Brain 133:286–299.
3. Agosta F, Galantucci S, Canu E, Cappa SF, Magnani G, Franceschi M et al (2013) Disruption of structural connectivity along the dorsal and ventral language pathways in patients with nonfluent and semantic variant primary progressive aphasia: A DT MRI study and a literature review. Brain Lang 127:157–166.
4. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW (2007) Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 4:7.
5. Armstrong RA (2016) Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: Effects of genetic, demographic and neuropathological variables. Folia Neuropathol 54:137–148.
6. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77:639–646.
7. Ayala YM, Misteli T, Baralle FE (2008) TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin dependent kinase 6 expression. Proc Natl Acad Sci USA 105:3785–3789.
8. Baborie A, Griffiths TD, Jaros E, Perry R, McKeith IG, Burn DJ et al (2015) Accumulation of dipeptide repeat proteins predates that of TDP-43 in Frontotemporal Lobar Degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropath Appl Neurobiol 41:601–612.
9. Baker M, Mackenzie IRA, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C et al (2006) Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919.
10. Bathgate D, Snowden JS, Varma A, Blackshaw A, Neary D (2001) Behaviour in frontotemporal dementia: A comparison with Alzheimer's disease and vascular dementia. Acta Neurol Scand 103:367–378.
11. Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF et al (2008) A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131:706–720.
12. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P et al (2009) TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 65:470–473.
13. Bigio EH, Lipton AM, White CL, III, Dickson DW, Hirano A (2003) Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: Additional evidence for overlap between FTD and ALS. Neuropathol Appl Neurobiol 29:239–253.
14. Boeve BF (2007) Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy and amyotrophic lateral sclerosis. Alzheimer Dis Assoc Disord 21:S31–S38. 3
15. Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O et al (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135:765–783.
16. Bramham CR, Wells DG (2007) Dendritic mRNA: transport, translation and function. Nature Rev Neurosci 8:776–789.
17. Brellstaff J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R et al (2011) Transportin 1: A marker for FTLD-FUS. Acta Neuropathol 122:591–600.
18. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20–38.
19. Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB et al (2014) Sequential distribution of pTDP-43 pathology in behavioural variant frontotemporal dementia (bvFTD). Acta Neuropathol 127:423–439.
20. Brown J, Ashworth A, Gydesen S, Sorensen A, Rossor M, Hardy J et al (1995) Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 4:1625–1628.
21. Buratti E, Baralle FE (2008) Multiple roles of TDP-43 in gene expression, splicing regulation and human disease. Front Bioscience 13:867–878.
22. Burrell JR, Halliday GM, Kril JJ, Ittner LM, Gotz J, Kiernan MC et al (2016) The frontotemporal dementia-motor neuron disease continuum. Lancet 388:919–931.
23. Cairns NJ, Perry RH, Jaros E, Burn D, McKeith IG, Lowe JS et al (2003) Patients with a novel neurofilamentopathy: Dementia with neurofilament inclusions. Neurosci Lett 341:177–180.
24. Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH et al (2004) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63:1376–1384.
25. Cairns NJ, Zhuckareva V, Uryu K, Zhang B, Bigio E, Mackenzie IR et al (2004) Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 164:2153–2161.
26. Chen-Plotkin AS, Martinez-Lage M, Sleiman PMA, Hu W, Greene R, Wood EM et al (2011) Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol 68:488–497.
27. Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, Castanedes-Casey M et al (2015) Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348:1151–1154.
28. Chiu WZ, Kaat LD, Seelaar H, Rosso SM, Boon AJ, Kamphorst W et al (2010) Survival in progressive supranuclear palsy and frontotemporal dementia. J Neurol Neurosurg Psychiatry 81:441–445.
29. Clark LN, Poorkaj P, Wzsolek Z, Geschwind DH, Nasreddine ZS, Miller B et al (1998) Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 95:13103–13107.
30. Coleman LW, Digre KB, Stephenson GM, Townsend JJ (2002) Autopsy proven, sporadic Pick disease with onset at age 25 years. Arch Neurol 59:856–859.
31. Cooper-Knock J, Walsh MJ, Higginbottom A, Highley RJ, Dickman MJ, Edbauer D et al (2014) Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 137:2040–2051.
32. Cooper-Knock J, Higginbottom A, Stopford MJ, Highley RJ, Ince PG, Wharton SB et al (2015) Antisense RNA foci in the motor neurones of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol 130:63–75.
33. Coyle-Gilchrist IT, Dick KM, Patterson K, Vazquez-Rodriquez P, Wehmann E, Wilcox A et al (2016) Prevalence, characteristics and survival of frontotemporal lobar degeneration syndromes. Neurology 86:1736–1743.
34. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924.
35. Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113:521–533.
36. Davidson YS, Robinson AC, Hu Q, Mishra M, Baborie A, Jaros E et al (2013) Nuclear Carrier and RNA Binding Proteins in Frontotemporal Lobar Degeneration associated with Fused in Sarcoma (FUS) pathological changes. Neuropathol Appl Neurobiol 39:157–165.
37. Davidson Y, Barker H, Robinson AC, Troakes C, Smith B, Al-Sarraj S et al (2014) Brain distribution of dipeptide repeat proteins in Frontotemporal Lobar Degeneration and Motor Neurone Disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2:70.
38. Davidson Y, Robinson AC, Liu X, Wu D, Troakes C, Rollinson S et al (2016) Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol Appl Neurobiol 42:242–254.
39. Davion S, Johnson N, Weintraub S, Mesulam M-M, Engberg A, Michra M et al (2007) Clinicopathologic correlation in PGRN mutations. Neurology 69:1113–1121.
40. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256.
41. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–215.
42. De Silva R, Lashley T, Strand K, Shiarli AM, Shi J, Tian J et al (2006) An immunohistochemical study of cases of sporadic and inherited Frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol 111:329–340.
43. Devenney E, Hornberger M, Irish M, Mioshi E, Burrell J, Tan R et al (2014) Frontotemporal dementia associated with the C9ORF72 mutation. A unique clinical profile. JAMA Neurol 71:331–339.
44. Fletcher PD, Downey LE, Golden HL, Clark CN, Slattery CF, Paterson RW et al (2015) Auditory hedonic phenotypes in dementia: A behavioural and neuroanatomical analysis. Cortex 67:95–105.
45. Fletcher PD, Downey LE, Golden HL, Clark CN, Slattery CF, Paterson RW et al (2015) Pain and temperature processing in dementia: A clinical and neuroanatomical analysis. Brain 138:3360–3372.
46. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB et al (2006) Frontotemporal dementia: Clinicopathological correlations. Ann Neurol 59:952–962.
47. Fujita K, Ito H, Nakano S et al (2008) Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. Acta Neuropathol 118:439–445.
48. Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N (2011) A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble TAR DNA binding protein-43 inclusions. J Biol Chem 286:18664–18672.
49. Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A et al (2013) Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: Late-onset psychotic clinical presentation. Biol Psychiatry 74:384–391.
50. Gami P, Murray C, Schottlaender L, Bettencourt C, De Pablo Fernandez E, Mudanohwo E et al (2015) A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. Acta Neuropathol 130:599–601.
51. Gitcho MA, Baloh AH, Chakraverty S, Mayo K, Norton JB, Levitch D et al (2008) TDP-43 A315T mutation in familial motor neurone disease. Ann Neurol 63:535–538.
52. Goedert M, Jakes R, Crowther RA (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 450:306–311.
53. Gomez-Deza J, Lee Y-B, Troakes C, Nolan M, Al-Sarraj S, Gallo J-M et al (2015) Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutatant amyotrophic lateral sclerosis and are unlikely to cause their neurodegeneration. Acta Neuropathol Commun 3:38.
54. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014.
55. Govaarts R, Beeldman E, Kamelmacher MJ, von Tol MJ, van den Berg LH, van der Kooi AJ et al (2016) The frontotemporal syndrome of ALS is associated with poor survival. J Neurol 263:2476–2483.
56. Gydesen S, Hagen S, Klinken L, Abelskov J, Sørensen SA (1987) Neuropsychiatric studies in a family with presenile dementia different from Alzheimer and Pick disease. Acta Psychiatr Scand 76:276–284.
57. Hardy J, Rogaeva E (2014) Motor Neurone Disease and frontotemporal dementia: Sometimes related, sometimes not. Exp Neurol 262:75–83.
58. Harris JM, Gall C, Thompson JC, Richardson AM, Neary D, du Plessis D et al (2013) Classification and pathology of primary progressive aphasia. Neurology 81:1832–1839.
59. Harris JM, Jones M, Gall C, Richardson AM, Neary D, du Plessis D et al (2016) Co-occurrence of language and behavioural change in frontotemporal lobar degeneration. Dement Geriatr Cogn Dis Extra 6:205–213.
60. Hasegawa M, Smith MJ, Goedert M (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 437:207–210.
61. Hayashi S, Toyoshima Y, Hasegawa M, Umeda Y, Wakabayashi K, Tokiguchi S et al (2002) Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol 51:525–530.
62. He Z, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 1:600–612.
63. He Z, Ong CH, Halper J, Bateman A (2003) Progranulin is a mediator of the wound response. Nature Med 9:225–229.
64. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G (2003) Survival in frontotemporal dementia. Neurology 61:349–354.
65. Hodges JR, Patterson K (2007) Semantic dementia: A unique clinicopathological syndrome. Lancet Neurol 6:1004–1014.
66. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P et al (2010) Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 133:300–306.
67. Hogg M, Grujic ZM, Baker M, Demirci S, Guillozet AL, Sweet AP et al (2003) The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol 106:323–336.
68. Holm IE, Englund E, Mackenzie IRA, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol 66:884–891.
69. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914–1917.
70. Hsiung G-YR, DeJesus-Hernandez M, Feldman HH, Sengdy P, Bouchard-Kerr P, Dwosh E et al (2012) Clinical and pathological features of familial Frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 135:709–722.
71. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H et al (1998) Association of missense and 5'-splice mutations in tau with the inherited FTDP-17. Nature 393:702–705.
72. Ioannidis P, Konstantinopoulou E, Maiovis P, Karacostas D (2012) The frontotemporal dementias in a tertiary referral center: Classification and demographic characteristics in a series of 232 cases. J Neurol Sci 318:171–173.
73. Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM et al (2015) Frontotemporal lobar degeneration: Defining phenotypic diversity through personalized medicine. Acta Neuropathol 129:469–491.
74. Isaacs AM, Johannsen P, Holm I, Nielsen JE, FReJA Consortium (2011) Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res 8:246–251.
75. Jacob J, Revesz T, Thom M, Rossor MN (1999) A case of sporadic Pick disease with onset at 27 years. Arch Neurol 56:1289–1291.
76. Janssen JC, Warrington EK, Morris HR, Lantos P, Brown J, Revesz T et al (2002) Clinical features of Frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology 58:1161–1168.
77. Johnson J, Diehl-Schmid J, Mendez M, Neuhaus J, Shapira J, Forman MS et al (2005) Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 62:925–930.
78. Josephs KA, Holton JL, Rossor MN, Braendgaard H, Ozawa T, Fox NC (2003) Neurofilament inclusion body disease: a new proteinopathy?. Brain 126:2291–2303.
79. Josephs KA, Knopman DS, Whitwell JL, Boeve BF, Parisi JE, Petersen RC et al (2005) Survival in two variants of tau-negative frontoemporal lobar degeneration: FTLS-U vs FTLD-MND. Neurology 65:645–647.
80. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE et al (2006) Clinicopathological correlates of progressive aphasia and apraxia of speech. Brain 129:1385–1398.
81. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR et al (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66:41–48.
82. Josephs KA, Whitwell JL, Vemuri P, Senjem ML, Boeve BF, Knopman DS et al (2008) The anatomic correlate of prosopagnosia in semantic dementia. Neurology 71:1628–1633.
83. Josephs KA, Whitwell JL, Parisi JE, Petersen RC, Boeve BF, Jack CR, Jr et al (2010) Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 17:969e7.
84. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM et al (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:137–153.
85. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C et al (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet 40:572–574.
86. Kansal K, Mareddy M, Sloane KL, Minc AA, Rabins PV, McGready JB et al (2016) Survival in frontotemporal dementia phenotypes: A meta-analysis. Dement Geriatr Cogn Disord 41:109–122.
87. Kertesz A, Ang LC, Jesso S, MacKinley J, Baker M, Brown P et al (2013) Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: A detailed clinical cohort. Cogn Behav Neurol 26:146–154.
88. Knopman DS, Roberts RO (2011) Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45:330–335.
89. Kobylecki C, Jones M, Thompson JC, Richardson AM, Neary D, Mann DM et al (2015) Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia. J Neurol 262:916–222.
90. Kwiatkowski TJ, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208.
91. Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T et al (2014) Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345:1139–1145.
92. Landqvist WM, Gustafson L, Passant U, Englund E (2015) Psychotic symptoms in frontotemporal dementia: A diagnostic dilemma?. Int Psychogeriatr 27:531–539.
93. Lashley T, Rohrer JD, Brandopadhyay R, Fry C, Ahmed Z, Isaacs AM et al (2011) A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134:2548–2564.
94. Le Ber I, Guedj E, Gabelle A, Verpillat P, Volteau M, Thomas-Anterion C et al (2006) Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 129:3051–3065.
95. Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M et al (2007) Progranulin null mutations in both sporadic and familial Frontotemporal dementia. Hum Mutation 28:846–855.
96. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A et al (2008) Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study. Brain 131:732–746. 2008;
97. Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G et al (2013) SQSTM1 mutations in French patients with Frontotemporal Dementia or Frontotemporal Dementia with Amyotrophic Lateral Sclerosis. JAMA Neurol 70:1403–1410.
98. Mackenzie IRA, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E et al (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129:3081–3090.
99. Mackenzie IRA, Neumann M, Bigio E, Cairns NJ, Alafuzoff I, Krill J et al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: Consensus recommendations. Acta Neuropathol 117:15–18.
100. Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113.
101. Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K et al (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: Clinico-pathological correlations. Acta Neuropathol 126:859–879.
102. Mann DMA, Yates PO (1974) Motor Neurone Disease: The nature of the pathogenetic mechanism. J Neurol Neurosurg Psychiat 37:1036–1046.
103. Mann DMA, Rollinson S, Robinson A, Callister J, Snowden JS, Gendron T et al (2013) Dipeptide repeat proteins are present in the p62 positive inclusions in patients with Frontotemporal Lobar Degeneration and Motor Neurone Disease associated with expansions in C9ORF72. Acta Neuropathol Comm 1:68.
104. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y et al (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465:223–226.
105. May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM et al (2014) C9orf72 FTLD/ALS-associated Gly-Alal dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128:485–503.
106. Mendez MF, Shapira JS, Woods RJ, Licht EA, Saul RE (2008) Psychotic symptoms in frontotemporal dementia: Prevalence and review. Dement Geriatr Cogn Disord 25:206–211.
107. Mesulam M-M, Wieneke C, Thompson C, Rogalski E, Weintraub S (2012) Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain 135:1537–1353.
108. Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P et al (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 126:845–858.
109. Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A et al (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345:1192–1194.
110. Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K et al (2013) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 126:881–894.
111. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335–1338.
112. Munoz D, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S et al (2009) FUS pathology in Basophilic Inclusion Body disease (BIBD). Acta Neuropathol 118:617–627.
113. Murrell JR, Spillantini MG, Zolo P, Guazzelli M, Smith MJ, Hasegawa M et al (1999) Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol 58:1207–1226.
114. Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M et al (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 447:195–199.
115. Neary D, Snowden JS, Mann DMA, Northen B, Goulding PJ, MacDermott N (1990) Frontal lobe dementia and motor neurone disease. J Neurol Neurosurg Psychiatry 53:23–32.
116. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al (1998) Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546–1554.
117. Neary D, Snowden JS, Mann DMA (2007) Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathol 114:31–38.
118. Neumann M, Schulz-Schaeffer W, Crowther RA, Smith MJ, Spillantini MG, Goedert M et al (2001) Pick's disease associated with the novel tau gene mutation K369I. Ann Neurol 50:503–513.
119. Neumann M, Sampathu DM, Kwong LK, Chou TT, Micsenyi M, Truax A et al (2006) TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133.
120. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IRA (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931.
121. Neumann M, Roeber S, Kretzschmar H, Mackenzie IRA (2009) Abundant FUS pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616.
122. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O et al (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:2595–2609.
123. Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 4:124–134.
124. Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psych 25:130–137.
125. O'Rourke JG, Bogdanik L, Muhammad AK, Gendron TF, Kim KJ, Austin A et al (2015) C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88:892–901.
126. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J et al (2015) Human C9ORF72 Hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88:902–909.
127. Pickering Brown SM, Richardson AM, Snowden JS, McDonagh AM, Burns A, Braude W et al (2002) Inherited frontotemporal dementia in 9 British families associated with intronic mutations in the tau gene. Brain 125:732–751.
128. Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AMT et al (2008) Frequency and clinical characteristics of progranulin mutation carriers in the Manchester Frontotemporal Lobar Degeneration cohort: Comparison to patients with MAPT and no known mutations. Brain 131:721–731.
129. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R et al (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130:77–92.
130. Proudfoot M, Gutowski NJ, Edbauer D, Hilton DA, Stephens M, Rankin J et al (2014) Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol 127:451–458. 2014
131. Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P et al (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: An international initiative. Lancet Neurol 6:857–868.
132. Ranasinghe KG, Rankin KP, Pressman PS, Perry DC, Lobach IV, Seeley WW et al (2016) Distinct subtypes of behavioral variant frontotemporal dementia based on patterns of network degeneration. JAMA Neurol 73:1078–1088.
133. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477.
134. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268.
135. Rizzini C, Goedert M, Hodges J, Smith MJ, Jakes R, Hills R et al (2000) Tau gene mutation K257T causes a tauopathy similar to Pick's disease. J Neuropathol Exp Neurol 59:990–1001.
136. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A et al (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 64:414–421.
137. Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J et al (2009) The heritability and genetics of frontotemporal lobar degeneration. Neurology 73:1451–1456.
138. Rohrer JD, Rosser M, Warren JD (2010) Syndromes of nonfluent primary progressive aphasia. A clinical and neurolinguistics analysis. Neurology 75:603–610.
139. Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs A et al (2010) The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatr 82:1405–1407.
140. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM et al (2011) Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 134:2565–2581.
141. Rosso SM, Donker Kaat L, Baks T, Joose M, de Koning I, Pijnenburg Y et al (2003) Frontotemporal dementia in the Netherlands: Patient characteristics and prevalence estimates from a population-based study. Brain 126:2016–2022.
142. Sajjadi SA, Patterson K, Arnold RJ, Watson PC, Nestor PJ (2012) Primary progressive aphasia: A tale of two syndromes and the rest. Neurology 78:1670–1677.
143. Saxon JA, Harris JM, Thompson JC, Jones M, Richardson AMT, Langheinrich T et al (2017) Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry in press.
144. Schludi MH, May S, Grässer FA, Rentzsch K, Kremmer E, Küpper C et al (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130:537–555.
145. Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A et al (2011) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol 257:747–753.
146. Shi J, Shaw CL, Richardson AMT, Bailey K, Julien C, Stopford C et al (2005) Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol 110:501–512.
147. Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K et al (2014) Psychosis in frontotemporal dementia. J Alzheimers Dis 42:485–499.
148. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H et al (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genet 37:806–808.
149. Smethurst P, Newcombe J, Troakes C, Simone R, Chen Y-R, Patani R et al (2016) In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis 6:236–247.
150. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M et al (2012) Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 90:1102–1107.
151. Snowden JS, Bathgate B, Varma A, Blackshaw A, Gibbons ZC, Neary D (2001) Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 70:323–332.
152. Snowden JS, Neary D, Mann DMA (2004) Autopsy proven, sporadic frontotemporal dementia, due to microvacuolar histology, with onset at 21 years of age. J Neurol Neurosurg Psychiatry 75:1337–1339.
153. Snowden JS, Thompson JC, Neary D (2004) Knowledge of famous faces and names in semantic dementia. Brain 127:860–872.
154. Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D et al (2006) Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129:3091–3102.
155. Snowden JS, Pickering-Brown SM, Du Plessis D, Mackenzie IRA, Varma A, Mann DMA et al (2007) Progressive anomia revisited: focal degeneration associated with progranulin gene mutation. Neurocase 13:366–377.
156. Snowden JS, Hu Q, Rollinson S, Halliwell N, Robinson A, Davidson YS et al (2011) The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 122:99–110.
157. Snowden JS, Thompson JC, Stopford CL, Richardson AMT, Gerhard A, Neary D et al (2011) Clinical diagnosis of early-onset dementias: Diagnostic accuracy and clinico-pathological relationships. Brain 134:2478–2492.
158. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM et al (2012) Distinct clinical and pathological characteristics in patients with frontotemporal dementia and C9ORF72 mutations. Brain 135:693–708.
159. Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A et al (2015) Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lat Sclerosis Frontotemporal Degeneration 16:497–505.
160. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95:7737–7741.
161. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672.
162. Thompson SA, Patterson K, Hodges JR (2003) Left/right asymmetry of atrophy in semantic dementia: Behavioral-cognitive implications. Neurology 61:1196–1203.
163. Thorpe JR, Tang H, Atherton J, Cairns NJ (2008) Fine structural analysis of the neuronal inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm 115:1661–1671.
164. Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M et al (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135:3380–3391.
165. Turner BJ, Baumer D, Parkinson NJ, Scaber J, Ansorge O, Talbot K (2008) TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neuroscience 9:104–114.
166. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A et al (2010) FUS pathology defines the majority of tau-and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120:33–41.
167. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211. 2
168. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genet 42:234–239.
169. Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R, Vandenbulcke M et al (2013) Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol 70:365–373.
170. Van Swieten JC, Heutink P (2008) Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 7:965–974.
171. Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A et al (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:3202–3216.
172. Wang IF, Wu LS, Chang HY, Shen CK (2008) TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 105:797–806.
173. Waite AJ, Bäumer D, East S, Neal J, Morris HR, Ansorge O et al (2014) Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 35:1779.e5–1779.e13.
174. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D et al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genet 36:377–381.
175. Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y et al (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84:1213–1225.
176. Whitwell JL, Weigand SD, Boeve BF, Senjem ML, Gunter JL, DeJesus-Hernandez M et al (2012) Neuroimaging signatures of frontotemporal dementia genetics: C9orf72, tau, progranulin and sporadics. Brain 135:794–806.
177. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283:13302–13309.
178. Yu C-E, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E et al (2010) The spectrum of mutations in progranulin: A collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161–170.
179. Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL et al (2014) Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol 128:505–524.
180. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM et al (2002) Conversion of proepithelin to epithelins: Roles of SLPI and elastase in host defense and wound repair. Cell 111:867–878.
181. Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J et al (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA 110:E4968–E4977.